PRESS RELEASE published on 09/17/2025 at 14:00, 10 months 24 days ago Inside Information / Other news releases Medincell and Teva to discuss Phase 3 Olanzapine LAI data from SOLARIS Trial at 2025 Psych Congress. Webcast details available on Teva's IR website Phase 3 Medincell Teva SOLARIS Trial Olanzapine LAI
BRIEF published on 09/12/2025 at 07:35, 11 months ago Medincell Appoints Three New Board Members Innovation Biopharmaceutical Leadership Board Appointments Medincell
PRESS RELEASE published on 09/12/2025 at 07:30, 11 months ago Inside Information / Other news releases Medincell appoints Dr. Sharon Mates, Dr. Charles Kunsch, and Dr. Pascal Touchon to its Board of Directors, adding valuable expertise in biotech and pharmaceutical sectors Board Of Directors Medincell Dr. Sharon Mates Dr. Charles Kunsch Dr. Pascal Touchon
BRIEF published on 09/10/2025 at 21:46, 11 months 1 day ago UZEDY® Obtains Approval in South Korea Following Success in the United States Schizophrenia UZEDY Teva Handok Medical Supply Korean Market
PRESS RELEASE published on 09/10/2025 at 21:41, 11 months 1 day ago Inside Information / Other news releases Teva Handok announces regulatory approval for UZEDY® in South Korea by Ministry of Food and Drug Safety, following successful US launch. Medincell's long-acting injectable for schizophrenia shows strong commercial performance Regulatory Approval Schizophrenia Medincell Commercial Performance Teva Handok
BRIEF published on 08/04/2025 at 14:05, 1 year ago Medincell Announces its 2025 General Meeting Governance General Meeting Resolutions Remuneration Medincell
BRIEF published on 07/30/2025 at 14:34, 1 year ago Medincell's Rising Revenue and Upcoming Submissions Schizophrenia Treatment Teva Partnership Medincell Revenue UZEDY Sales Olanzapine Submission
PRESS RELEASE published on 07/30/2025 at 14:29, 1 year ago INSIDE INFORMATION / OTHER NEWS RELEASES Medincell's partner Teva Pharmaceuticals raises 2025 revenue outlook for UZEDY® to $190–$200M and confirms Olanzapine LAI on track for submission in 2025 Revenue Outlook Medincell Teva Pharmaceuticals Olanzapine LAI Submission
BRIEF published on 07/30/2025 at 13:47, 1 year ago Medincell's UZEDY® and Olanzapine LAI Forecast Promising Financial Outcomes Schizophrenia Treatment Teva Pharmaceuticals Medincell Revenue Forecast UZEDY® Performance Olanzapine LAI Development
PRESS RELEASE published on 07/30/2025 at 13:42, 1 year ago Inside Information / Other news releases Medincell's partner Teva increases 2025 revenue outlook for UZEDY® to $190–$200M, plans olanzapine LAI submission. Company's innovative treatments aim to improve medicine accessibility Revenue Outlook Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
Published on 08/12/2026 at 08:02, 47 minutes ago Southern Energy Corp. Announces Spudding of Cotton Valley Test Well at Williamsburg and Appointment of Market Maker
Published on 08/12/2026 at 08:00, 49 minutes ago Galantas Selects Engineering and Mine Planning Contractors for Andacollo Gold Project
Published on 08/12/2026 at 00:00, 8 hours 49 minutes ago Organto Foods Reports Record Second Quarter 2026 Financial Results
Published on 08/11/2026 at 23:40, 9 hours 9 minutes ago RJK Explorations Ltd. Announces Private Placement for Gross Proceeds of up to $100,000
Published on 08/11/2026 at 23:15, 9 hours 34 minutes ago Fermi and Hillcore Energy Capital Announce 2.6 Gigawatt Power Strategic Alliance for Project Matador
Published on 08/12/2026 at 08:30, 19 minutes ago VINCI Energies announces start of acceptance period for €67.50-per-share cash offer to All for One shareholders
Published on 08/12/2026 at 08:11, 38 minutes ago hGears Group achieved results in line with expectations in the first half of 2026 and confirms the guidance
Published on 08/12/2026 at 08:05, 44 minutes ago Zurich Group Germany Accelerates Digital Transformation with Move to Guidewire Cloud
Published on 08/12/2026 at 08:00, 49 minutes ago Viscom SE increases order intake by 30% in the first half of 2026 – Significant rise in the order book lays a solid foundation for the second half of the year; full-year forecast for 2026 confirmed
Published on 08/12/2026 at 07:57, 52 minutes ago Medios continues growth path in the first half of 2026 and focuses on profitability and cash conversion
Published on 08/10/2026 at 18:00, 1 day 14 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 11:53, 1 day 20 hours ago GUILLEMOT CORPORATION | Information regarding the total number of voting rights and shares 31/07/2026
Published on 08/10/2026 at 11:36, 1 day 21 hours ago GUILLEMOT CORPORATION| Weekly report share buyback from August 3 to August 7 2026
Published on 08/10/2026 at 09:22, 1 day 23 hours ago Number of shares and voting rights - July 2026 (In French only)
